Ensysce Biosciences, Inc. (ENSC)

Market Cap	2.63M
Revenue (ttm)	5.21M
Net Income (ttm)	-7.99M
Shares Out	1.41M
EPS (ttm)	-11.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	81,761
Open	1.690
Previous Close	1.660
Day's Range	1.678 - 1.900
52-Week Range	1.620 - 14.670
Beta	1.07
Analysts	n/a
Price Target	n/a
Earnings Date	May 12, 2025

About ENSC

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company’s lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 8
• Stock Exchange: NASDAQ
• Ticker Symbol: ENSC
• Website: https://www.ensysce.com

Financial Performance

In 2024, Ensysce Biosciences's revenue was $5.21 million, an increase of 133.58% compared to the previous year's $2.23 million. Losses were -$7.99 million, -24.83% less than in 2023.